By Professor Richard Bryan Lock

Journal articles

Marshall GM; Norris MD; Lock RB; Peaston AE; Gardaneh M; Franco VA; Hocker JE; Murphy K; Farnsworth ML; Catchpoole DR; Haber M, 2001, 'MRP1 gene expression level regulates the death and differentation response of neuroblastoma cells', British Journal of Cancer, 85, pp. 1564 - 1571, http://dx.doi.org/10.1054/bjoc.2001.2144

Catchpoole DR; Lock RB, 2001, 'The Potential Tumour Suppressor role for caspase-9 in the childhood malignancy, neoroblastoma', European Journal of Cancer, pp. 2217 - 2221

Murphy KD; Streips UN; Lock RB, 2000, 'Bcl-2 inhibits a Fas-induced conformational change in the Bas N terminus and Bax mitchondrial translocation', The Journal of Biological Chemistry, pp. 17225 - 17228

Murphy KD; Ranganathan V; Farnsworth ML; Kavallaris M; Lock RB, 2000, 'Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumour cells', Cell death and differentiation, pp. 102 - 111

Turnbull RM; Meczes EL; Rogers MP; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA, 1999, 'Carbamate analogues of amsacrine active against non-cycling cells: Relative activity against topoisomerases IIα and β', Cancer Chemotherapy and Pharmacology, 44, pp. 275 - 282, http://dx.doi.org/10.1007/s002800050978

Murphy KD; Streips UN; Lock RB, 1999, 'Bax membrane insertion during Fas (CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2', Oncogene, 18, pp. 5991 - 5999

Elliott MJ; Murphy KD; Stribinskiene L; Ranganathan V; Sturges E; Farnsworth ML; Lock RB, 1999, 'Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide', Cancer Chemotherapy and Pharmacology, pp. 1 - 11

Turnbull RM; Meczes EL; Rogers M; Lock RB; Sullivan DR; Finlay GJ; Baguley BC; Austin CA, 1999, 'Carbanate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases II and B', Cancer Chemotherapy and Pharmacology, pp. 275 - 282

Elliot M; Stribinskiene L; Lock RB, 1998, 'Expression of Bcl-2 in human epithelial tumor (HeLA) cells enhances clonogenic survival following exposure to 5-fluoro-2-deoxyuridine or staurosporine, but not following exposure to etoposide or dosorubicin', Cancer Chemotherapy and Pharmacology, pp. 457 - 463

LaRocca RV; Lock RB, 1998, 'Surveying the frontiers of cancer research and therapy', Louisville Medicine, 45, pp. 511 - 513

Lock RB; Thompson BS; Sullivan DM; Stribinskiene L, 1997, 'Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation', Cancer Chemother Pharmacol, 39, pp. 399 - 409

Lock RB; Thompson BS; Stribinskiene L, 1996, 'Differential ability of 2,4-dinitrophenol to modulate etoposide cytotoxicity in mammalian tumor cell lines associated with inhibition of macromolecular synthesis', Int J Oncology, 8, pp. 305 - 311

Lock RB; Stribinskiene L, 1996, 'Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival', Cancer Research, 56, pp. 4006 - 4012

Sullivan DM; Feldhoff PW; Lock RB, 1995, 'Characterization of an altered DNA topoisomerase IIα from a mitoxantrone resistant mammalian cell line which is hypersensitive to DNA crosslinking agents', Int J Oncology, 7, pp. 1383 - 1393

Eastman A; Grant S; Lock R; Tritton T; Van Houten N; Yuan J, 1994, 'Cell Death in Cancer and Development', Cancer Research, 54, pp. 2812 - 2818

Lock RB; Galperina OV; Feldhoff RC; Rhodes LJ, 1994, 'Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells', Cancer Research, 54, pp. 4933 - 4939

Lock RB; Keeling PK, 1993, 'Responses of HeLa and Chinese hamster ovary p34cdc2/cyclin-B kinase in relation to cell cycle perturbations induced by etoposide', Int J Oncology, 3, pp. 33 - 42

Lock RB, 1992, 'Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide', Cancer Research, 52, pp. 1817 - 1822

Webb CD; Latham MD; Lock RB; Sullivan MD, 1991, 'Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line', Cancer Research, 51, pp. 6543 - 6549

Lock RB; Ross WE, 1990, 'Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells', Cancer Research, 50, pp. 3761 - 3766

Lock RB; Ross WE, 1990, 'Possible role for p34cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells', Cancer Research, 50, pp. 3767 - 3771

Shen J-W; Subjeck JR; Lock RB; Ross WE, 1989, 'Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response', Mol Cell Biol, 9, pp. 3284 - 3291

Hill BT; Whelan RDH; Hosking LK; Shellard SA; Bedford P; Lock RB, 1988, 'Interactions between antitumor drugs and radiation in mammalian tumor cell lines: Differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro', Nci Monographs, pp. 177 - 181

Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RPEA, 1988, 'Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I', Cancer Research, 48, pp. 6404 - 6410

Lock RB; Hill BT, 1988, 'Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines', Int J Cancer, 42, pp. 373 - 381

Hill BT; Whelan RDH; Hosking LK; Shellard SA; Bedford P; Lock RB, 1988, 'Interactions between antitumor drugs and radiation in mammalian tumor cell lines: differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro', NCI Monographs, 6, pp. 171 - 181

Hill BT; Whelan RDH; Bellamy AS; Lock RB, 1988, 'The differential expression of drug resistance or collateral sensitivity in a continuous human tumor cell line established from a squamous cell carcinoma of the tongue following in vitro exposure to fractionated X-irradiation', , pp. 167 - 173

Lock RB; Ross WE, 1987, 'DNA topoisomerases in cancer therapy', Anti-Cancer Drug Design, 2, pp. 151 - 164

Bellamy AS; Whelan RDH; Lock RB; Hill BT, 1987, 'Effects of fractionated X-irradiation on subsequent response to acute X-irradiation in two human tumour cell lines in vitro', Int J Radiat Biol, 51, pp. 681 - 691

LOCK RB; HILL BT, 1986, 'Drug resistance in vitro: interactions between X-irradiation, etoposide and vincristine', Biochemical Society Transactions, 14, pp. 618 - 619, http://dx.doi.org/10.1042/bst0140618

Conference Papers

Starobova H; McCalmont H; Shatunova S; Tay N; Winkler I; Robertson A; Lock R; Vetter I, 2024, 'NEUROINFLAMMATION DRIVES ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY-INDUCED NEUROPATHY', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, CANADA, Montreal, pp. S77 - S78, presented at Annual Meeting of the Peripheral-Nerve-Society (PNS), CANADA, Montreal, 22 June 2024 - 25 June 2024

Tyrrell V; Mayoh C; Ekert P; Cowley M; Ziegler D; Wong M; Barahona P; Pinese M; Haber M; Salomon R; Courtney E; Lock R; Fuentes-Bolanos N; Marshall G; Warby M; Trahair T; Dong AKQ; Wakefield C; Tucker K; Barlow-Stewart K; Padhye B; Lau L, 2024, 'Zero Childhood Cancer National Precision Medicine Program: Improving outcomes for children with high risk cancer cancer utilising comprehensive, integrated multiomic profiling', in EUROPEAN JOURNAL OF HUMAN GENETICS, SPRINGERNATURE, GERMANY, Berlin, pp. 800 - 800, presented at 57th Conference of the European-Society-of-Human-Genetics (ESHG), GERMANY, Berlin, 01 June 2024 - 04 June 2024

Tremblay C; Saw J; Boyle J; Haigh K; Lock R; Jane S; Haigh J; Curtis D, 2023, 'STAT5 ACTIVATION PROMOTES PROGRESSION AND CHEMOTHERAPY-RESISTANCE IN EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA', in EXPERIMENTAL HEMATOLOGY, ELSEVIER SCIENCE INC, NY, New York, pp. S151 - S151, presented at 52nd Annual Meeting of the International-Society-for-Experimental-Hematology (ISEH), NY, New York, 17 August 2023 - 20 August 2023

Xie J; Gifford A; Mao J; Cadiz R; Avila A; Yun DY; Zhou A; Dolman E; Fleuren E; Mayoh C; Barahona P; Lau L; Kamili A; Tsoli M; Marshall G; Ziegler D; Trahair T; Haber M; Tyrrell V; Lock R, 2022, 'Establishment and application of patient-derived xenograft models for personalised medicine in paediatric cancer', Sydney, presented at Children’s Cancer Institute - Research Symposium 2022, Sydney, 06 December 2022

Fordham A; Brown L; Mayoh C; Wong M; Barger Z; O'Regan L; Lim Kan Siam T; Xie J; Gunther K; Barahona P; Ajuyah P; Lau L; Ziegler D; Haber M; Tyrrell V; Lock R; Cowley M; Nicholls W; Daly R; Ekert P; Fleuren E, 2022, 'MULTI-PLATFORM TYROSINE KINASE PROFILING REVEALS NOVEL ACTIONABLE FGFR ABERRATIONS ACROSS PEDIATRIC AND ADOLESCENT AND YOUNG ADULT SARCOMAS', Vancouver, Canada, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting 2022, Vancouver, Canada, 17 November 2022

Lock RB; Evans K; Randall J; Erickson SW; Earley EJ; Neuhauser S; Stearns T; Philip V; Teicher BA; Watkins K; Sloss CM; Zweidler-McKay PA; Smith MA, 2022, 'Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, pp. 8983 - 8984, http://dx.doi.org/10.1182/blood-2022-159867

Lock RB; Evans K; Watts B; Randall J; Toscan CE; Earley EJ; Erickson SW; Belmontes B; Wong P; Teicher BA; Hughes PE; Smith MA, 2022, 'Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, pp. 11690 - 11691, http://dx.doi.org/10.1182/blood-2022-159885

Connerty P; Moles E; deBock C; Jayatilleke N; Smith JL; Meshinchi S; Mayoh C; Kavallaris M; Lock RB, 2021, 'Abstract P143: Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for paediatric acute myeloid leukaemia', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. p143 - p143, http://dx.doi.org/10.1158/1535-7163.targ-21-p143

Fordham A; Brown L; Mayoh C; Wong M; Barger Z; Xie J; Gunther K; Trebilcock P; Lock R; Cowley M; Ekert P; Fleuren E, 2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma', Sydney (virtual), presented at Kids Cancer Alliance (KCA) Symposium 2021, Sydney (virtual), 02 September 2021

Lock RB; Evans K; El-Zein N; Lannutti BJ; Jessen KA; Earley EJ; Erickson SW; Smith MA; Kurmasheva R; Houghton PJ, 2021, 'Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)', in Cancer Research, American Association for Cancer Research (AACR), pp. 3038 - 3038, http://dx.doi.org/10.1158/1538-7445.am2021-3038

Lock RB; Evans K; El-Zein N; Earley EJ; Erickson SW; Teicher BA; Smith MA, 2021, 'Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 3039 - 3039, http://dx.doi.org/10.1158/1538-7445.am2021-3039

Lock RB; Evans K; El-Zein N; Earley EJ; Erickson SW; Teicher BA; Sung V; Smith MA, 2021, 'Abstract LB171: The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL)', in Cancer Research, American Association for Cancer Research (AACR), pp. lb171 - lb171, http://dx.doi.org/10.1158/1538-7445.am2021-lb171

Fleuren E; Dolman E; Lau L; Xie J; Batey D; Mayoh C; Barahona P; Khuong Quang DA; Wong M; ZERO PDTT; ZERO OT; Norris M; Haber M; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Lock R; Ekert P, 2021, 'Supporting clinical decision-making for PI3K/AKT/mTOR inhibitors for high-risk paediatric and adolescent and young adult (AYA) sarcoma', Virtual, presented at The Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Annual Scientific Meeting, Virtual, 24 June 2021

Fordham A; Brown L; Mayoh C; Wong M; Barger Z; Xie J; Gunther K; Trebilcock P; Lim Kam Sian T; Lock R; Daly R; Cowley M; Ekert P; Fleuren E, 2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma.', Virtual, presented at The Australian Society for Medical Research (ASMR) 2021, Virtual, 10 June 2021

Fleuren E; Dolman E; Lau L; Xie J; Batey D; Mayoh C; Barahona P; Sherstyuk A; Khuong Quang DA; Wong M; ZERO PDTT; ZERO OT; Thomas D; Mould E; Norris M; Haber M; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Lock R; Ekert P, 2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric and AYA sarcoma', Virtual, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting 2020, Virtual, 18 November 2020

Fleuren E; Dolman E; Lau L; Xie J; Batey D; Mayoh C; Barahona P; Khuong Quang DA; Wong M; ZERO PDTT; ZERO OT; Norris M; Haber M; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Lock R; Ekert P, 2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric sarcoma patients', Virtual, presented at KCA Symposium 2020, Virtual, 17 September 2020

Lock RB; Evans K; Jones CD; Erickson SW; Teicher BA; Unger T; Landesman Y; Smith MA, 2020, 'Abstract 4181: The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes', in Cancer Research, American Association for Cancer Research (AACR), pp. 4181 - 4181, http://dx.doi.org/10.1158/1538-7445.am2020-4181

Haber M; Gamble L; Xiao L; Pandher R; Somers K; Murray J; Khan A; Yu D; Franshaw L; Burns MR; Tsoli M; Ehteda A; Cesare A; O’Connor A; Mussai F; de Santo C; Cheng P; Korotchkina L; Gurova K; Tyrrell V; Mould E; Lau L; Quang DAK; Mayoh C; Arndt G; Barahona P; Failes T; Fletcher J; Bolanos NF; Gauthier M-E; Gifford A; Grebert-Wade D; Kamili A; Kumar A; Nagabushan S; O’Brien T; Strong P; Sherstyuk A; Thomas D; Trahair T; Tucker K; Warby M; Wong M; Xie J; Evans K; Lock R; Chernova OB; Henderson M; Gudkov AV; Ekert P; Cowley MJ; Marshall GM; Ziegler DS; Norris MD, 2020, 'Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in Cancer Research, American Association for Cancer Research (AACR), pp. ia13 - ia13, http://dx.doi.org/10.1158/1538-7445.pedca19-ia13

Fleuren E; Lau L; Barahona P; Sherstyuk A; Mayoh C; Terry R; Khuong Quang DA; Wong M; Xie J; Batey D; Grebert-Wade D; Strong P; Lim JY; Chow S-O; Kumar A; Failes T; Arndt G; Mould E; Haber M; Norris M; Lock R; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Ekert P, 2020, 'Precision medicine for high-risk paediatric and AYA sarcomas', Lorne, presented at Lorne Cancer 2020, Lorne, 13 February 2020

Lock RB; Toscan CE; Jing D; Mayoh C, 2019, 'Abstract A123: Reversal of glucocorticoid resistance in pediatric acute lymphoblastic leukemia is dependent on restoring BIM expression', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. a123 - a123, http://dx.doi.org/10.1158/1535-7163.targ-19-a123

Back to profile page